Hung Do
Plus aucun poste en cours
Profil
Hung Do a fondé Callidus Biopharma, Inc. Le Dr Do est directeur scientifique chez Amicus Therapeutics, Inc. Il a précédemment occupé le poste de directeur et de responsable scientifique en chef chez Callidus Biopharma, Inc, de chef de projet chez Genzyme Corp. et de directeur chez Novazyme Pharmaceuticals, Inc. Hung Do a obtenu un doctorat de l'université A&M du Texas.
Anciens postes connus de Hung Do
| Sociétés | Poste | Fin |
|---|---|---|
Callidus Biopharma, Inc.
 Callidus Biopharma, Inc. BiotechnologyHealth Technology Callidus Biopharma, Inc. develops drug discovery services. The firm focuses on enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Its novel technology platform is based on attaching a form of the naturally occurring Insulin-like growth factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The company was founded by Cuong Viet Do and Hung Do in 2010 and is headquartered in Bensalem, PA. | Founder | 01/11/2013 |
| AMICUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Novazyme Pharmaceuticals, Inc.
 Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | Corporate Officer/Principal | - |
Formation de Hung Do
| Texas A&M University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Callidus Biopharma, Inc.
Callidus Biopharma, Inc. BiotechnologyHealth Technology Callidus Biopharma, Inc. develops drug discovery services. The firm focuses on enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Its novel technology platform is based on attaching a form of the naturally occurring Insulin-like growth factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The company was founded by Cuong Viet Do and Hung Do in 2010 and is headquartered in Bensalem, PA. | Health Technology |
Novazyme Pharmaceuticals, Inc.
Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | Commercial Services |
